Literature DB >> 8406877

Plasmodium falciparum varies in its ability to induce tumor necrosis factor.

R J Allan1, A Rowe, D Kwiatkowski.   

Abstract

Tumor necrosis factor (TNF) has a variety of protective and pathological actions in human malaria. We report that different laboratory lines of Plasmodium falciparum which were derived from a single wild isolate (IT 4/25/5) varied widely in their ability to stimulate TNF production by human mononuclear cells. In the cloned line R29 we observed that subcultures selected for high rosetting frequency gave significantly higher levels of TNF stimulation than subcultures with low rosetting frequency, indicating that TNF induction can vary within populations that have originated from a single genotype. These results raise the possibility that the clinical severity of malaria is partly determined by the TNF-inducing activity of the infecting strain of parasite.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8406877      PMCID: PMC281233          DOI: 10.1128/iai.61.11.4772-4776.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  Mortality and morbidity from malaria among children in a rural area of The Gambia, West Africa.

Authors:  B M Greenwood; A K Bradley; A M Greenwood; P Byass; K Jammeh; K Marsh; S Tulloch; F S Oldfield; R Hayes
Journal:  Trans R Soc Trop Med Hyg       Date:  1987       Impact factor: 2.184

2.  Intercellular adhesion molecule-1 is an endothelial cell adhesion receptor for Plasmodium falciparum.

Authors:  A R Berendt; D L Simmons; J Tansey; C I Newbold; K Marsh
Journal:  Nature       Date:  1989-09-07       Impact factor: 49.962

3.  The glycoinositolphospholipid profiles of two Leishmania major strains that differ in lipophosphoglycan expression.

Authors:  M J McConville; A Bacic
Journal:  Mol Biochem Parasitol       Date:  1990-01-01       Impact factor: 1.759

4.  Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria.

Authors:  P Kern; C J Hemmer; J Van Damme; H J Gruss; M Dietrich
Journal:  Am J Med       Date:  1989-08       Impact factor: 4.965

5.  Anti-TNF therapy inhibits fever in cerebral malaria.

Authors:  D Kwiatkowski; M E Molyneux; S Stephens; N Curtis; N Klein; P Pointaire; M Smit; R Allan; D R Brewster; G E Grau
Journal:  Q J Med       Date:  1993-02

6.  Human malaria parasites in continuous culture.

Authors:  W Trager; J B Jensen
Journal:  Science       Date:  1976-08-20       Impact factor: 47.728

7.  Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria.

Authors:  G E Grau; L F Fajardo; P F Piguet; B Allet; P H Lambert; P Vassalli
Journal:  Science       Date:  1987-09-04       Impact factor: 47.728

8.  Tumour necrosis factor production in Falciparum malaria and its association with schizont rupture.

Authors:  D Kwiatkowski; J G Cannon; K R Manogue; A Cerami; C A Dinarello; B M Greenwood
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

9.  Tumor necrosis factor and disease severity in children with falciparum malaria.

Authors:  G E Grau; T E Taylor; M E Molyneux; J J Wirima; P Vassalli; M Hommel; P H Lambert
Journal:  N Engl J Med       Date:  1989-06-15       Impact factor: 91.245

10.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.

Authors:  C A Dinarello; J G Cannon; S M Wolff; H A Bernheim; B Beutler; A Cerami; I S Figari; M A Palladino; J V O'Connor
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

View more
  15 in total

1.  A target for intervention in Plasmodium falciparum infections.

Authors:  F E McKenzie; W H Bossert
Journal:  Am J Trop Med Hyg       Date:  1998-06       Impact factor: 2.345

Review 2.  Host-parasite interaction and morbidity in malaria endemic areas.

Authors:  K Marsh; R W Snow
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-09-29       Impact factor: 6.237

3.  Cellular basis of early cytokine response to Plasmodium falciparum.

Authors:  M Hensmann; D Kwiatkowski
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

4.  A monoclonal antibody that recognizes phosphatidylinositol inhibits induction of tumor necrosis factor alpha by different strains of Plasmodium falciparum.

Authors:  C A Bate; D Kwiatkowski
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

5.  Inhibitory immunoglobulin M antibodies to tumor necrosis factor-inducing toxins in patients with malaria.

Authors:  C A Bate; D Kwiatkowski
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

6.  Lack of an association between antibodies to Plasmodium falciparum glycosylphosphatidylinositols and malaria-associated placental changes in Cameroonian women with preterm and full-term deliveries.

Authors:  Amorsolo L Suguitan; D Channe Gowda; Genevieve Fouda; Lucy Thuita; Ainong Zhou; Rosine Djokam; Simon Metenou; Rose G F Leke; Diane Wallace Taylor
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

7.  Strain variation in tumor necrosis factor induction by parasites from children with acute falciparum malaria.

Authors:  R J Allan; P Beattie; C Bate; M B Van Hensbroek; S Morris-Jones; B M Greenwood; D Kwiatkowski
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

8.  Predominance of infected reticulocytes in the peripheral blood of CD4+ T-cell-depleted mice chronically infected with Plasmodium chabaudi chabaudi.

Authors:  A W Taylor-Robinson; R S Phillips
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

9.  Plasmodium falciparum rosetting is associated with malaria severity in Kenya.

Authors:  A Rowe; J Obeiro; C I Newbold; K Marsh
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

10.  Optimal tumor necrosis factor induction by Plasmodium falciparum requires the highly localized release of parasite products.

Authors:  Kieran P O'Dea; Geoffrey Pasvol
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.